Sponsored Links
| N30 Pharma Initiates Phase 1 Trials Of Novel Reductase Inhibitor |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
N30 Pharmaceuticals, LLC announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings... Read more: Irritable-Bowel Syndrome News From Medical News Today
|